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Microalbuminuria (MA) is associated with an in-
creased risk of cardiovascular disease in non-insulin-
dependent diabetes mellitus (NIDDM) [1–3], as well
as in the apparently healthy middle-aged and elderly
general population [4, 5]. It has been proposed that
MA belongs to a cluster of risk factors known as the
insulin resistance syndrome (IRS), which implies
that MA would be closely associated not only with
hypertension [6–9] and NIDDM [10, 11], but also
with impaired glucose tolerance (IGT) [10], obesity
[12, 13], insulin resistance (IR) [6, 8, 9, 11, 14], hyper-
insulinaemia [15, 16] and dyslipidaemia [6, 16, 17].
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Summary Microalbuminuria is a strong predictor of
cardiovascular disease. The aim of this study was to
investigate whether microalbuminuria is part of a
cluster of risk factors, the insulin resistance syndrome
(IRS), or whether it is only associated with, and pre-
sumably a complication of, hypertension and non-in-
sulin-dependent diabetes mellitus (NIDDM). An
age-, sex- and glucose tolerance-stratified random
sample from a 50–75 year old general population
(n = 622) was investigated. The urinary albumin-to-
creatinine ratio was measured in an early morning
spot urine sample. Microalbuminuria was defined as
an albumin-to-creatinine ratio greater than 2.0 mg/
mmol. We considered, as IRS-related variables, fast-
ing hyperinsulinaemia, insulin resistance (IR; calcu-
lated from the formula of the homeostasis model as-
sessment), dyslipidaemia, glucose intolerance, hyper-
tension and waist-to-hip ratio (WHR). Dyslipidaemia
was defined as levels of HDL-cholesterol in the low-
est and / or levels of triglyceride in the highest tertile.
Fasting insulin levels, IR and WHR were divided into
tertiles; the highest tertiles were compared to the
lowest tertiles. Age-, sex- and glucose tolerance-ad-
justed analyses showed microalbuminuria to be sig-
nificantly associated with hypertension, NIDDM
and WHR. In multiple logistic regression analyses,
microalbuminuria showed independent associations
with hypertension, NIDDM and WHR, with odds
ratios (ORs [95% confidence interval]) of 3.33
(1.86–5.96), 2.26 (1.14–4.48) and 2.49 (1.09–5.70), re-
spectively. No associations were found with impaired
glucose tolerance, hyperinsulinaemia, IR or dyslip-
idaemia. Multiple logistic regression analyses in dia-
betic and non-diabetic subjects separately showed
that microalbuminuria was independently associated
only with hypertension (ORs 4.31 and 2.69). In this
Caucasian population, microalbuminuria was associ-
ated with hypertension, NIDDM and WHR and not
with other variables of the IRS. It is therefore likely
that microalbuminuria is a complication of hyperten-
sion and NIDDM, and not an integral part of the
IRS. [Diabetologia (1998) 41: 694–700]
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These associations might then explain the association
between MA and the increased risk of cardiovascular
disease [6–11, 14–18]. Alternatively, MA may be a
complication of hypertension and NIDDM, possibly
reflecting endothelial dysfunction [19, 20], without
having associations with other components of the
IRS [21–23]. The latter hypothesis, if correct, implies
that MA cannot be used as a marker for the IRS in
the general population.
Previous experimental [6, 8, 9, 11, 14, 17, 22] and
epidemiological [7, 10, 15, 16, 18, 21, 23] investiga-
tions of the link between MA and the IRS have yield-
ed conflicting results. These studies have, however,
been limited by not being population-based [6–9, 11,
18, 21, 22], by including only part of the spectrum of
glucose tolerance and the IRS [6–11, 14, 16, 17, 21,
23], and / or by not being ethnically homogeneous
[10, 18, 23]. The latter is important, because the prev-
alence and the pathogenesis of MA may differ ac-
cording to ethnicity. For example, non-Caucasian
populations showed higher prevalences of MA than
Caucasian populations, both among subjects with
NIDDM [23–25] as well as among non-diabetic sub-
jects [16, 18, 25]. In view of these considerations, we
decided to study the association between MA and
the IRS in a population-based, sex-, age- and glucose
tolerance- stratified sample of an ethnically homoge-
neous, Caucasian population.
Subjects and methods
Subjects. The Hoorn Study is a cross-sectional survey of glu-
cose intolerance and related complications in 2484 randomly
selected Caucasian men and women aged 50–75 years as de-
scribed in detail elsewhere [26]. Of this population, an age-,
sex- and glucose tolerance-stratified sample of 680 subjects
(279 with normal glucose tolerance [NGT], 219 with IGT and
182 with NIDDM [27]; based on one oral glucose tolerance
test [OGTT]); 95.5 % of those invited underwent a second
OGTT (except those subjects with previously diagnosed NID-
DM treated with oral blood glucose-lowering agents or insulin,
n = 67 [26]) and were asked to collect urine for measurement
of the albumin-to-creatinine ratio (see below). The final defi-
nition of glucose tolerance was based on the mean of the two
OGTTs (314 NGT, 192 IGT and 174 NIDDM subjects [27]).
All participants gave their informed consent for these studies,
which were approved by the local ethics committee.
Methods. Blood pressure, weight and height were measured
and body mass index and waist-to-hip ratio (WHR) were cal-
culated as previously described [26]. Information on smoking
habits and protein intake was obtained by a self-administered
questionnaire. We measured fasting and 2-h post-load venous
plasma glucose levels, HbA1c, fasting plasma levels of insulin
(with a specific assay) and proinsulin, and fasting serum levels
of total cholesterol, HDL cholesterol and triglycerides, as de-
scribed in detail elsewhere [26, 28]. Fasting proinsulin levels
were not measured in previously diagnosed NIDDM (n = 67).
The Friedewald formula was used to calculate the LDL choles-
terol concentration, except when serum triglyceride was great-
er than 8.0 mmol/l (n = 3) [29].
An early morning first voided spot urine sample was col-
lected. The presence of leukocytes was tested by microscopy
and scored as positive ( > 5 leukocytes per high powerfield) or
negative. Urinary albumin was measured by rate nephelome-
try (Array Protein System, Beckman, Galway, Ireland) with a
threshold of 6.2 mg/l and intra- and inter-assay coefficients of
variation of 5 % and 8 %, respectively. Urinary creatinine was
measured by a modified JaffØ method. The urinary albumin-
to-creatinine ratio (ACR) was calculated; ACR K 2.0 mg/
mmol was defined as normoalbuminuria and ACR above
2.0 mg/mmol as microalbuminuria. (An overnight ACR >
2.0 mg/mmol predicts an albumin excretion rate > 30 mg/min
with a high sensitivity and specificity [30].) The reproducibility
of the ACR was calculated from a representative sample of 185
subjects who collected a second urine sample in similar fash-
ion. The Kappa coefficient of the ACRs in these subjects was
0.59, indicating moderate agreement [31]. The analyses were
performed on 622 subjects of the initial 680; 24 urine samples
were lost and 34 subjects used angiotensin converting enzyme
inhibitors and were therefore excluded. For 174 subjects the
ACR was based on the mean of two measurements. Six sub-
jects had an ACR above 30 mg/mmol, a level which approxi-
mates an albumin excretion of 300 mg/24 h, i. e. the upper limit
for microalbuminuria. Excluding these subjects from the anal-
yses did not materially affect any of the results, which are
therefore presented for the entire group.
Statistical analysis. All analyses were performed with the Sta-
tistical Package for the Social Sciences (SPSS). We postulated
that if MA was part of the IRS, MA should be related not
only to hypertension and NIDDM (of which MA may be a
complication, as suggested by the alternative hypothesis de-
scribed above), but also to dyslipidaemia, central obesity and
hyperinsulinaemia or IR. Therefore, multiple logistic regres-
sion analyses were performed to investigate the association be-
tween the presence of MA and IRS-related variables. The
Wald test was used to test significance. All odds ratios for MA
were adjusted for age, sex and glucose tolerance. We used
three different models, in which each separate variable was ad-
justed for the other IRS-related variables. In the first, we con-
sidered, as IRS-related variables, fasting hyperinsulinaemia,
dyslipidaemia, glucose intolerance (i. e. IGT or NIDDM), hy-
pertension and WHR [32, 33]. In the second, fasting hyperinsu-
linaemia was replaced by IR, according to the formula of the
homeostasis model assessment: IR = fasting insulin ´ fasting
glucose / 22.4 [34]. (We chose fasting rather than post-glucose
insulin levels as an estimate of IR, because fasting but not
post-glucose insulin levels have been shown to correlate close-
ly with insulin-mediated glucose uptake in both NGT and
NIDDM [35].) In the third model, fasting hyperproinsulina-
emia, another possible marker of IR [36], replaced fasting hy-
perinsulinaemia. Hypertension was defined as diastolic blood
pressure over 95 mmHg and / or systolic blood pressure over
160 mmHg and / or the use of antihypertensive drugs. Dyslip-
idaemia was defined as levels of HDL-cholesterol in the lowest
and / or triglycerides in the highest tertile. Fasting insulin lev-
els, IR and WHR (separate per sex) were divided into tertiles;
the highest tertiles were compared to the lowest.
Finally, to investigate as thoroughly as possible the putative
association of MA with the IRS, we created two sum’ Z-scores
for each subject. For each IRS-related variable a Z-score ((val-
ue( ´ ) – mean( ´ )) / sd( ´ )) was calculated. The first sum’ Z-
score was the sum of the Z-scores of the continuous variables
reflecting NIDDM and hypertension, i. e. fasting glucose level
and systolic and diastolic blood pressure. The second sum’ Z-
score was the sum of Z-scores of the other IRS-related vari-
ables, i. e. fasting levels of insulin, triglycerides and HDL-cho-
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lesterol, and WHR, a higher Z-score indicating a more unfa-
vourable spectrum. The idea of this analysis is that weak asso-
ciations between MA and these other IRS-related variables
might reveal themselves when considered in combination,
even if each of these associations were too weak to be signifi-
cant by themselves. Thus, to investigate whether higher sum’
Z-scores were associated with a higher risk of MA, we calculat-
ed the prevalence of MA in all combinations of tertiles of the
two sum’ Z-scores.
Results
The prevalence of MA in this sample was 10.9% (68/
622) and was higher among diabetic than among
non-diabetic subjects (21.3 vs 7.5%) and among hy-
pertensive than among non-hypertensive subjects
(20.1 vs 5.8%; Fig.1). The prevalence of MA, in the
general 50–75-year-old Caucasian population of
Hoorn, age-standardized to the age distribution in
the general population and calculated by direct stan-
dardisation, was 8.2% (22.6% and 6.9% among dia-
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Fig.1. Age-standardized prevalence of microalbuminuria in
different glucose tolerance groups with or without hyperten-
sion, = normotensive subjects, R = hypertensive subjects,
NGT = normal glucose tolerance, IGT = impaired glucose tol-
erance, NIDDM = non-insulin-dependent diabetes mellitus.
Table 1. Baseline characteristics of subjects with normo- and microalbuminuria
Normal glucose tolerance sub-
jects
Impaired glucose tolerance sub-
jects
Diabetic subjects
ACR K 2.0
mg/mmol
ACR > 2.0
mg/mmol
ACR K 2.0
mg/mmol
ACR > 2.0
mg/mmol
ACR K 2.0
mg/mmol
ACR > 2.0
mg/mmol
n 275 20 157 15 122 33
Sex (%male) 50 65 45 53 46 33
Age (years) 63 ± 7 68 ± 6 65 ± 7 65 ± 7 66 ± 7 67 ± 6
Fasting glucose (mmol/l) 5.4 (5.1–5.7)a 5.5 (5.1–5.8)a 5.9 (5.5–6.6)a 6.0 (5.9–6.4)a 7.5 (6.4–8.5)a 7.0 (6.1–8.4)a
HbA1c (% of haemoglobin) 5.4 ± 0.5 5.2 ± 0.5 5.6 ± 0.5 5.6 ± 0.4 7.0 ± 1.9 8.0 ± 1.7
Fasting insulin (pmol/l) 79 (60–97)a 80 (66–110)a 93 (72–126)a 79 (65–151)a 116 (83–162)a 131 (82–168)a
Hyperinsulinaemia (%)b 18 30 41 40 55 58
Insulin resistance
(pmol · mmol × l 2)c
19 (14–23)a 20 (16–26)a 25 (18–34)a 20 (18–46)a 38 (26–57)a 44 (31–66)a
Insulin resistance (%)d 8 5 36 47 74 82
Fasting proinsulin (pmol/l) 9 (5–14)a 13 (7–19)a 13 (8–21)a 16 (9–24)a 22 (12–31)a 23 (9–42)a
Body mass index (kg/m2) 26.0 ± 3.4 26.9 ± 3.6 27.9 ± 4.0 27.1 ± 3.8 28.2 ± 4.1 29.7 ± 5.4
Waist-to-hip ratio (female) 0.83 ± 0.07 0.88 ± 0.06 0.88 ± 0.07 0.87 ± 0.07 0.91 ± 0.08 0.94 ± 0.05
Waist-to-hip ratio (male) 0.94 ± 0.06 0.99 ± 0.06 0.98 ± 0.06 0.96 ± 0.06 0.99 ± 0.08 0.99 ± 0.06
Total cholesterol (mmol/l) 6.7 ± 1.1 6.1 ± 1.0 6.8 ± 1.3 6.7 ± 1.3 6.4 ± 1.3 6.6 ± 1.3
LDL-cholesterol (mmol/l) 4.6 ± 1.0 4.2 ± 0.9 4.7 ± 1.1 4.5 ± 1.1 4.2 ± 1.1 4.2 ± 1.1
HDL-cholesterol (mmol/l) 1.4 ± 0.4 1.3 ± 0.4 1.3 ± 0.3 1.2 ± 0.3 1.1 ± 0.3 1.1 ± 0.3
Triglycerides (mmol/l) 1.4 (1.1–1.9)a 1.2 (0.8–1.4)a 1.6 (1.2–2.2)a 2.4 (1.6–2.9)a 1.9 (1.3–2.7)a 1.5 (1.2–4.4)a
Diastolic blood pressure (mmHg) 81 ± 10 81 ± 10 83 ± 9 93 ± 13 82 ± 10 84 ± 13
Systolic blood pressure (mmHg) 133 ± 18 137 ± 20 141 ± 17 156 ± 28 140 ± 18 153 ± 19
Hypertension (%)e 21 40 42 73 46 79
Current smokers (%) 30 25 22 13 24 24
Ex-smokers (%) 34 50 36 53 34 39
Data are mean ± standard deviation unless otherwise indicat-
ed. a median (25–75 th percentiles); b percentage of subjects
with fasting insulin levels in the highest tertile in the whole
sample (> 101 pmol/l); c HOMA= fasting insulin  fasting glu-
cose/22.4; d percentages of subjects with IR in the highest ter-
tile in the whole sample (> 29.8 pmol × mmol × l 2); e Hyper-
tension is defined as diastolic blood pressure > 95 mmHg and/
or systolic blood pressure > 160 mmHg and/or the use of anti-
hypertensive drugs
betic and non-diabetic subjects, 16.4% and 5.9%
among hypertensive and non-hypertensive subjects,
and 5.4% among normotensive non-diabetic sub-
jects).
Among NGT subjects, those with MA were older
and had higher WHR and systolic blood pressure
than did those with normoalbuminuria. Among dia-
betic subjects, HbA1 c and systolic blood pressure
were higher in the micro- than in the normoalbumin-
uric subjects. Thirty-eight percent of the diabetic sub-
jects were previously known diabetic subjects. The IR
and fasting insulin levels were similar between newly
detected and previously known diabetic subjects
(data not shown). Among NGT, IGT and NIDDM
subjects, the prevalence of hypertension was higher
among those with compared to those without MA
(Table 1).
Age-, sex- and glucose tolerance-adjusted analyses
showed MA to be significantly associated with hyper-
tension, NIDDM and WHR (Table 2). MA was asso-
ciated with hypertension and WHR in the non-dia-
betic subjects and with hypertension among diabetic
subjects. Analyses of NGT and IGT subjects sepa-
rately showed MA to be associated with hypertension
and WHR but not with the other IRS-related vari-
ables (data not shown). As a consequence of the low
prevalence of MA among NGT and IGT subjects
(20/295 and 15/172, respectively), these analyses
were unstable.
To further investigate the association between MA
and IRS-related variables, multiple logistic regres-
sion analyses were performed with age, sex, NIDDM,
IGT, hypertension, fasting hyperinsulinaemia, dyslip-
idaemia and WHR as independent variables. MA was
significantly associated with NIDDM, hypertension
and WHR. Analyses of the non-diabetic and the dia-
betic subjects separately showed similar results (Ta-
ble 3), as did multiple regression analyses with IR or
hyperproinsulinaemia replacing hyperinsulinaemia
(i. e. the second and third model referred to in the
Data analysis section; data not shown). We also inves-
tigated whether the association between MA and
WHR was confounded by protein intake by perform-
ing analyses with daily protein intake (total, animal
or vegetable; g/kg/day) in the regression model; there
was no confounding (data not shown).
The above analyses suggested that hypertension
and NIDDM were major determinants of MA, while
other IRS-related variables were not. To investigate
this issue further, we created two Z-scores (see Sub-
jects and methods). The prevalence of MA increased
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Table 2. Age-, sex- and glucose tolerance-adjusted odds ratios (95 % confidence intervals) for microalbuminuria of insulin resis-
tance syndrome-related variables
All subjects (n = 622) Non-diabetic subjects (n = 467) Diabetic subjects (n = 155)
Hypertension 3.29 (1.86–5.82) 2.72 (1.31–5.67) 3.99 (1.56–10.22)
NIDDMa 3.35 (1.83–6.12)
Impaired glucose toleranceb 1.21 (0.60–2.45) 1.24 (0.61–2.51)
Dyslipidaemiac 1.14 (0.66–1.96) 1.06 (0.50–2.23) 1.07 (0.47–2.44)
Waist-to-hip ratiod, e 2.41 (1.10–5.29) 2.49 (1.02–6.05) 3.67 (0.45–30.15)
Fasting hyperinsulinaemiaf 1.39 (0.68–2.84) 1.56 (0.61–4.00) 0.93 (0.30–2.89)
Insulin resistanceg 1.84 (0.78–4.36) 1.45 (0.51–4.15) 1.96 (0.23–16.86)
Fasting hyperproinsulinaemiah,i 1.62 (0.65–4.01) 2.33 (0.84–6.46) 0.30 (0.04–2.06)
a compared to subjects with normal glucose tolerance; b com-
pared to subjects with normal glucose tolerance; c defined as
HDL-cholesterol in the lowest and/or triglycerides levels in
the highest tertile; d the highest compared to the lowest tertile
of waist-to-hip ratio per sex; e associations with BMI were
weaker; f highest (> 101 pmol/l) compared to the lowest tertile
of fasting insulin levels; g according to the HOMA-formula
(= fasting insulin  fasting glucose/22.4), comparing the high-
est (> 29.8 pmol × mmol × l 2) with the lowest tertile of insulin
resistance; h the highest (> 15.7 pmol/l) compared to the lowest
tertile of fasting proinsulin levels; i obtained in all subjects ex-
cept for the previously known diabetic subjects
Table 3. Multiple logistic regression analyses with microalbu-
minuria as dependent variable and insulin resistance syn-
drome-related variables as independent variables
OR (95% CI) p -value
All subjects (n = 622)
Non-insulin-dependent diabetes
mellitus
2.26 (1.14–4.48) 0.02
Hypertension 3.33 (1.86–5.96) 0.0001
Fasting hyperinsulinaemiaa 0.97 (0.46–2.06) 0.93
Dyslipidaemiab 0.79 (0.44–1.42) 0.43
Waist-to-hip ratioc 2.49 (1.09–5.70) 0.03
Non-diabetic subjects (n = 467)
Impaired glucose tolerance 0.93 (0.43–2.00) 0.86
Hypertension 2.69 (1.25–5.75) 0.01
Fasting hyperinsulinaemiaa 0.96 (0.34–2.68) 0.93
Dyslipidaemiab 0.77 (0.35–1.69) 0.51
Waist-to-hip ratioc 2.67 (1.04–5.75) 0.04
Diabetic subjects (n = 155)
Hypertension 4.31 (1.60–11.56) 0.004
Fasting hyperinsulinaemiaa 0.86 (0.26–2.86) 0.81
Dyslipidaemiab 0.72 (0.29–1.77) 0.74
Waist-to-hip ratioc 3.78 (0.41–34.74) 0.24
Age, sex, non-insulin-dependent diabetes mellitus, impaired
glucose tolerance, hypertension, fasting hyperinsulinaemia,
dyslipidaemia and waist-to-hip ratio were independent vari-
ables adjusted for each other; a the highest compared to the low-
est tertile of fasting insulin levels, b defined as HDL-cholesterol
in the lowest and/or triglycerides in the highest tertile, c the
highest compared to the lowest tertile of waist-to-hip ratio per
sex; OR = odds ratio; 95 % CI = 95 % confidence interval
when the Z-score of glucose level and systolic and di-
astolic blood pressure increased, but not when the Z-
score of the remaining IRS-related variables in-
creased (Fig.2). Sex- and age-adjusted regression
analyses with these two Z-scores as independent vari-
ables showed a significant association with MA for
the Z-score of blood pressure and fasting glucose
(OR 1.89[1.32–2.70]), but not for the Z-score of the
other IRS-related variables (OR = 1.39[0.98–2.00]).
These results were similar for non-diabetic and dia-
betic subjects separately (data not shown).
We repeated the multiple regression analyses for
the 174 subjects who had handed in two urine sam-
ples, for one sample only and for the mean of two
samples. The results were similar, i. e. only hyperten-
sion and NIDDM were statistically significantly asso-
ciated with MA (data not shown). We also investigat-
ed whether the definition of MA affected the results.
However, the results of the multiple regression analy-
ses were similar, whether MA was defined as an ACR
over 2.5 mg/mmol for men and an ACR over 3.5 mg/
mmol for women ([37]; prevalence, 7.7% [48/622]),
as an ACR 1.5 mg/mmol for both sexes ([4]; preva-
lence, 15.1% [94/622]), or as ACR over 2.0 mg/
mmol while excluding subjects with leukocyturia
(n = 136; data not shown).
Discussion
This study shows that, in an ethnically homogeneous,
Caucasian population aged 50–75 years, MA is
strongly associated with hypertension, NIDDM and
WHR, but not with other components of the IRS,
i. e. insulin resistance, hyperinsulinaemia and dyslip-
idaemia. This suggests that MA is more likely to be a
complication of NIDDM and (or) hypertension than
a part of the IRS.
MA is thought to be a consequence of an increased
leakage of albumin through the glomerular basement
membrane as a result of increased intraglomerular
capillary pressure, increased permeability of the
glomerular capillary wall, or both [38]. Both hyper-
tension and NIDDM can increase intraglomerular
pressure [39]; hyperglycaemia, moreover, can induce
loss of negative charges on the glomerular basement
membrane and thus increase permeability to nega-
tively charged proteins such as albumin [40]. Thus,
there is a clear pathophysiological basis for the asso-
ciation of MA with NIDDM and hypertension, which
strongly suggests that MA can arise as a complication
of these phenomena. In contrast, there is no conclu-
sive evidence that insulin resistance, hyperinsulin-
aemia or dyslipidaemia increase intraglomerular
pressure and / or impair glomerular charge selectivity
and thus lead directly to MA [41, 42]. Taken together,
these findings argue against MA being an integral
part of the IRS.
We did find that WHR, as a marker of central obe-
sity, was associated with the presence of MA indepen-
dently of NIDDM and hypertension. Recently, it has
been reported that an increased urinary albumin ex-
cretion is associated with a higher body mass index
[13]. One might argue that the association of central
obesity with MA is consistent with the concept that
MA is a part of the IRS. If this were the case, howev-
er, it is difficult to explain why MA turned out not to
be associated with the other components of the IRS.
In addition, several other mechanisms unrelated to
the IRS may account for the association between cen-
tral obesity and MA. Firstly, obese subjects may have
a higher protein intake, which may increase the intra-
glomerular pressure [43]. In the present study, how-
ever, protein intake did not explain the association
between WHR and MA. Secondly, recent data indi-
cate that central adipose tissue may be a source of cy-
tokines such as tumour necrosis factor-a [44], which
can increase glomerular permeability [45]. Finally,
through mechanisms that have not been elucidated,
the overweight condition may be associated with re-
nal haemodynamic changes, such as hyperperfusion
and hyperfiltration, that tend to increase intraglomer-
ular pressure [46].
Previous cross-sectional [6, 8, 11, 14] and prospec-
tive [9] studies have shown that IR, as determined
with the euglycaemic hyperinsulinaemic clamp tech-
nique, was more severe in the presence of MA than
in its absence. However, these studies were perform-
ed in highly selected subjects and cannot establish
whether MA is intrinsically linked to IR and the IRS
in the general population. Epidemiological studies of
the associations of MA with IRS-related variables
have not yielded consistent results [7, 10, 16, 18,
21–23]. In our study we found no association between
MA and the IRS, even in Z-score analyses in which
weak associations might reveal themselves by being
A.Jager et al.: Microalbuminuria and the insulin resistance syndrome698
Lowest
0
Lowest
25
5
10
15
20
Pr
ev
a
le
nc
e 
of
 m
ic
ro
al
bu
m
in
u
ria
Middle Highest
Tertiles of Z-score 2
Tertiles of Z-score 1
Middle
Highest
Fig.2. Prevalence of microalbuminuria for different Z-scores.
Z-score 1 is the sum of the Z-scores of systolic and diastolic
blood pressure and fasting glucose levels, and Z-score 2 is the
sum of the Z-scores of waist-to-hip ratio, fasting insulin,
HDL-cholesterol and triglycerides levels
considered in combination. It is noteworthy that
some studies that reported a positive association be-
tween MA and the IRS did not adjust for (central)
obesity [6, 8, 14, 16], which would be desirable if (cen-
tral) obesity was linked to MA through mechanisms
independent of the IRS. In addition, the association
between MA and the IRS may be different among
different ethnic groups. It is remarkable that MA ap-
pears to be more closely related to hyperinsulinaemia
and dyslipidaemia in non-diabetic populations with a
low [10, 16] than in those with a high prevalence of
hypertension [18, 21]. Thus, if a link between MA
and the IRS does exist among non-diabetic subjects,
it seems to be most prominent among populations
with a low prevalence of hypertension.
Can methodological issues explain our results?
Firstly, we collected only one urine sample from most
subjects. As microalbuminuria is quite variable from
day-to-day, this may have decreased the overall statis-
tical power of the study. However, day-to-day variabil-
ity is probably lessened somewhat by collecting over-
night urine [47], as we did, and by expressing albumin
excretion as an albumin-to-creatinine ratio [48]. In ad-
dition, analyses for the 176 subjects from whom two
urine samples were collected yielded essentially simi-
lar results. Secondly, we chose an ACR over 2.0 mg/
mmol as the cut-off for MA. If the association between
MA and the IRS would depend on a certain threshold
for MA, we may have missed any such association by
our choice of the threshold. However, analyses with a
higher or a lower threshold gave similar results.
In conclusion, in an ethnically homogeneous, Cau-
casian population aged 50–75 years, the presence of
microalbuminuria was associated with the presence
of NIDDM and hypertension and with waist-to-hip
circumference ratio, but not with other components
of the IRS. We suggest that MA is not a useful marker
of the IRS in Caucasian populations. This contrasts
with data obtained in other ethnic groups [16]. Taken
together, these findings suggest that the relationship
between the IRS and MA may be modified by ethnic-
ity or related factors, such as the prevalence of hyper-
tension.
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